comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Comparative effectiveness of versus receptor on cardiovascular–kidney–metabolic stage progression: a real-world cohort study Cardiovascular outcomes trials for GLP-1
Description
GLP-1 receptor agonists work by slowing down stomach emptying
The only difference is the approved use printed on the label
A pre-clinical study showed that exendin-4 had a remarkable neuroprotective effect, improving the neurological deficit caused by transient middle cerebral artery occlusion in mice, and reducing neuronal loss and microglial inflammation (82)
Several prior meta-analyses have examined the cardiovascular effects of GLP-1RAs and, in some cases, included more studies
Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies
The bottom line: Retatrutide is promising to be a great tool for help with weight loss, but its not the only path forward for many people today
